Clinical trial perspective for adult and juvenile Huntington's disease using genetically-engineered mesenchymal stem cells

Progress to date from our group and others indicate that using genetically-engineered mesenchymal stem cells (MSC) to secrete brain-derived neurotrophic factor (BDNF) supports our plan to submit an Investigational New Drug application to the Food and Drug Administration for the future planned Phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Peter, Torrest, Audrey, Pollock, Kari, Dahlenburg, Heather, Annett, Geralyn, Nolta, Jan A., Fink, Kyle D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Invited Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904446/
https://www.ncbi.nlm.nih.gov/pubmed/27335539
http://dx.doi.org/10.4103/1673-5374.182682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904446/
https://www.ncbi.nlm.nih.gov/pubmed/27335539
http://dx.doi.org/10.4103/1673-5374.182682

Ejemplares similares